Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY: EBS )

9.520 +0.160 (+1.71%)
Official Closing Price Updated: 4:10 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
(EBS) - Analyzing Emergent BioSolutions's Short Interest
Via Benzinga
3 Promising Vaccine Stocks To Watch In The Event Of A Mpox Surge
Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains. 
Via Talk Markets
7 Analysts Assess Emergent BioSolutions: What You Need To Know
Via Benzinga
Why Emergent BioSolutions Stock Is Skyrocketing Today
Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump. 
Via The Motley Fool
H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Key Takeaways From Emergent BioSolutions Analyst Ratings
Via Benzinga
Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On?
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa. 
Via Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Via Benzinga
WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak
A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus. 
Via Benzinga
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
Emergent BioSolutions reported Q2 2024 sales of $254.7 million, beating estimates but showing a 25% decline year-over-year. Despite a significant adjusted EPS loss and mixed performance across product... 
Via Benzinga
Looking Into Emergent BioSolutions's Recent Short Interest
Via Benzinga
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
EBS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. 
Via Benzinga
How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
American Express offers an annual dividend yield of 1.12%, or $2.80 a year. How can investors pocket a regular $500 monthly? 
Via Benzinga
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
JNJ to release 2Q financial results on July 17. Expected earnings $2.70/share, revenue $22.29B. Investors eye 3.32% dividend yield for gains. 
Via Benzinga
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. 
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. 
Via Benzinga
Exposures COVID-19
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health and Human Services. The funding ensures the supply of critical medical... 
Via Benzinga
7 Top Stocks Under $10: June 2024 Edition
While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification. 
Via InvestorPlace
What Is Going On With Emergent BioSolutions Shares?
On Thursday prior to the market open, Emergent BioSolutions announced it entered into a definitive agreement with Bora to sell the site for about $30 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
7 Stocks to Buy Immediately Following Strong Earnings
These stocks to buy after earnings look good following especially strong earnings prints at each respective company in Q1. 
Via InvestorPlace
Vice Stock Vanguards: 3 Sin Stocks Delivering Heavenly Returns
While it might not feel right, consider these three sin stocks to buy, since the money is there to be made one way or another. 
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper highlights five stocks each week that are seeing increased attention from readers and partners. 
Via Benzinga
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171.08%. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.